PROactive Evaluation of Function to Avoid CardioToxicity



Status:Recruiting
Conditions:Breast Cancer, Cancer, Cancer, Cardiology, Lymphoma
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/20/2019
Start Date:March 13, 2019
End Date:December 31, 2022
Contact:Daniel J Lenihan, M.D., FACC
Email:djlenihan@wustl.edu
Phone:314-362-1291

Use our guide to learn which trials are right for you!

This study is intended to evaluate the ability of an intramyocardial strain analysis package
with cardiac MRI to assist in the early detection and management of cardiotoxicity from
therapeutics used to treat cancer.


Inclusion Criteria:

- Participant in the SURVIVE registry

- Signed informed consent form for PROACT

- Histological diagnosis of early or metastatic breast cancer, lymphoma, or sarcoma
(patients with treated and clinically stable brain metastasis are acceptable)

- Scheduled to receive anti-cancer therapy (radiation therapy is permitted)

Exclusion Criteria:

- Contraindication to magnetic resonance imaging (MRI)

- Unable to comply with study investigations (in the judgment of the investigator)

- Life expectancy less than 1 year
We found this trial at
4
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Daniel J Lenihan, M.D., FACC
Phone: 314-362-1291
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Vlad Zaha, M.D., Ph.D., FACC, FASE, FHFSA
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46237
Principal Investigator: Vijay Rao, M.D., Ph.D., FACC, FASE, FHFSA
Phone: 317-893-1900
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Lauren Baldassarre, M.D., FACC, FSCMR, FSCCT
?
mi
from
New Haven, CT
Click here to add this to my saved trials